BriaCell Therapeutics Corp.

Developing Novel Therapies to Destroy Cancer

Add To Watchlist
General Information
Company Name
BriaCell Therapeutics Corp.
Founded Year
2004
Location (Offices)
Philadelphia, United States +2
Founders / Decision Makers
Gadi Levin - CFO William Williams - President and CEO Charles Wiseman - Cofounder and Director
Number of Employees
20
Industries
Biotechnology, Health Care, Health and Wellness +1
Funding Stage
Post Ipo Equity
Social Media

BriaCell Therapeutics Corp. - Company Profile

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. The company achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. Currently, it is conducting a Phase I/IIa clinical trial of Bria-IMT™ in combination with a PD-1 inhibitor, retifanlimab provided by Incyte under a collaboration agreement. Additionally, BriaCell is developing Bria-OTS™, the first “off-the-shelf” personalized immunotherapy for advanced breast cancer. Established in 2004, the company operates in the biotechnology, health care, and pharmaceutical industries and is headquartered in the United States. Recently, the company secured a $5.00 million post-IPO equity investment on 15 May 2024. The investors involved in this investment round are not disclosed. For additional information on BriaCell, please visit their website: briacell.com.

Taxonomy: BriaCell Therapeutics Corp, Immunotherapy, Cancer Research, Oncology, Clinical Trials, Personalized Medicine, PD-1 Inhibitor, Immunotherapy Development, Cancer Immunotherapy, Breast Cancer Treatment, Targeted Therapies, Innovative Biotech, Therapeutic Innovations

Funding Rounds & Investors of BriaCell Therapeutics Corp. (3)

View All
Funding Stage Amount No. Investors Investors Date
Post-IPO Equity $5.00M - 15 May 2024
Post-IPO Equity $4.00M 1
Prevail Partners LLC, investor in BriaCell Therapeutics Corp.'s Post-IPO Equity round
15 May 2023
Post-IPO Equity $27.20M - 03 Jun 2021

Latest News of BriaCell Therapeutics Corp.

View All

No recent news or press coverage available for BriaCell Therapeutics Corp..

Similar Companies to BriaCell Therapeutics Corp.

View All
Umoja Biopharma - Similar company to BriaCell Therapeutics Corp.
Umoja Biopharma Pioneering advanced immunotherapies to empower the body's innate ability to fight cancer by reengineering immune cells directly within the patient.
Ohana Vaccines, LLC - Similar company to BriaCell Therapeutics Corp.
Ohana Vaccines, LLC A company devoted to developing and testing therapeutic cancer vaccines, currently for prostate cancer.
Immunowake, Inc. - Similar company to BriaCell Therapeutics Corp.
Immunowake, Inc. Immunowake Inc. is a private, pre-clinical stage biotechnology company focused on cancer drug discovery.
Sustainable Cell Therapeutics - Similar company to BriaCell Therapeutics Corp.
Sustainable Cell Therapeutics Pioneering cancer immunotherapy with a focus on patient rehabilitation and treatment of resilient and recurring cancers
Providence Health & Services - Similar company to BriaCell Therapeutics Corp.
Providence Health & Services Striving to cure cancer and cultivate a healthier world with innovative cancer immunotherapy research since 1993, based in Portland, OR.
Circle Decoration Circle Decoration

Want to dive deeper into BriaCell Therapeutics Corp.? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now